Ammax Bio Inc. has entered into an exclusive option with Evopoint Biosciences Co. Ltd. for a worldwide license, excluding Greater China, for the development and commercialization of a novel antibody-drug conjugate (ADC) for treating solid tumors.
Kronos Bio Inc. has entered into a discovery collaboration in the field of oncology with Genentech Inc., a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.
Entrada Therapeutics Inc. has selected a second clinical candidate within its Duchenne muscular dystrophy (DMD) franchise, ENTR-601-45, for the potential treatment of people living with DMD who are exon 45 skipping amenable. The company plans to submit an IND application in the second half of next year.
Researchers from Beam Therapeutics Inc. presented the discovery and preclinical evaluation of an engineered stem cell antibody paired evasion (ESCAPE) strategy for antibody (Ab)-mediated autologous hematopoietic stem cell (HSC) therapy conditioning for the treatment of hemoglobinopathies.
Aptevo Therapeutics Inc. has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 bispecific antibody, APVO-711, with the potential to treat a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma and carcinomas of the lung, gastrointestinal tract and colon.
Rocket Pharmaceuticals Inc. has added RP-A601 to its cardiac gene therapy portfolio for the treatment of arrhythmogenic cardiomyopathy due to plakophilin 2 pathogenic variants (PKP2-ACM).
Researchers from Institute of Medicinal Biotechnology have published details on the discovery of novel nonsteroidal farnesoid X receptor (FXR) agonists as potential therapeutic agents for the treatment of nonalcoholic steatohepatitis (NASH).
Blood vessels supplying adipose tissue in females and males differed in their biological characteristics and gene expression programs, researchers at York University in Toronto, Canada, have demonstrated. The findings, which will appear in the Jan. 20, 2023, print issue of Iscience after earlier publication online, give new insights into sex differences in metabolic health.
Fat tissue can be detrimental to health, but the relationship between fat, BMI and health is increasingly acknowledged as being highly complex. One factor that affects the relationship between fat and health is how well adipose tissue is vascularized. Any new tissue that forms in the body needs to be vascularized to ensure its blood supply, and fat is no exception.
Clearmind Medicine Inc. has released promising preclinical results demonstrating efficacy of its psychedelic-derived drug candidate MEAI for treating obesity and metabolic syndrome.
Boehringer Ingelheim Pharma GmbH & Co. KG and 3T Biosciences Inc. have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet needs.
RSS
